Get the Stockscreener App
27.66
2.95%
-0.84
Lb Pharmaceuticals Inc stock is traded at $27.66, with a volume of 160.31K.
It is down -2.95% in the last 24 hours and down -6.74% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$28.50
Open:
$28.74
24h Volume:
160.31K
Relative Volume:
0.69
Market Cap:
$793.20M
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-18.62
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
-5.50%
1M Performance:
-6.74%
6M Performance:
+39.56%
1Y Performance:
+0.00%
1-Day Range:
$27.37
$29.32
1-Week Range:
$27.37
$30.27
52-Week Range:
$13.36
$33.47
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
27.66 | 817.28M | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
All you need to know about LB Pharmaceuticals Inc (LBRX) rating upgrade to buy - MSN
Clear Street initiates LB Pharmaceuticals stock with buy rating - Investing.com
Clear Street initiates LB Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals Inc (LBRX) Edges Higher Amid Sector Strength – Key Levels in FocusPoint of Control - The Legal Advocate
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target - Investing.com UK
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential - TipRanks
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy - Yahoo Finance
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target By Investing.com - Investing.com Australia
LB Pharmaceuticals (LBRX) Edges Higher as Trading Activity Remains SteadyMACD Signal Stocks - newsline.com
LB Pharmaceuticals (LBRX) Holds Near Resistance as Modest Gain Signals ConsolidationHigh Volume Node - The Legal Advocate
LB Pharmaceuticals Inc (LBRX) Holds Steady Near Resistance as Market Watches for BreakoutCovered Call Trade - Newser
LB Pharmaceuticals Inc (LBRX) Breaks Higher as Volume Picks Up; Key Resistance AheadRetail Trader Picks - Newser
Why Is LB Pharmaceuticals Inc Common Stock (LBRX) Stock Down Today? - Meyka
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans - Sahm
Number of shareholders of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
TCG Crossover entities report 1.84M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Commodore Capital (LBRX) files Schedule 13G/A reporting 1.97M shares - Stock Titan
Caligan Partners discloses 1.44M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX) - The Globe and Mail
JPMorgan (NYSE: JPM) files amendment showing 1.43M LBRX shares (4.9%) - Stock Titan
This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders - TradingView
LB Pharmaceuticals (LBRX) reports $365.6M cash, Q1 net loss $19.1M - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) boosts cash for late-stage LB-102 trials - Stock Titan
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lb Pharmaceuticals Inc Stock (LBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
2,000,000 |
30,000,000 |
2,686,138 |
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):